analyzed pan-cancer datasets and discovered that mutations within the dsRNA-binding domain of ADAR1—particularly the R767 substitution impair dsRNA recognition, disrupt immune surveillance, and may promote tumor progression (92). Here, ADAR is linked to neoplasm.